by The cardiac valvulotome market has been witnessing significant growth over the past few years owing to the increasing prevalence of cardiovascular diseases such as mitral regurgitation and aortic stenosis. Cardiac valvulotomes are surgical devices used for removing vegetations from heart valves during cardiovascular procedures. The demand for cardiac valvulotomes has increased substantially with the rising caseload of transcatheter aortic valve replacement (TAVR) and mitral valve repair procedures globally.
The Global cardiac valvulotome market is estimated to be valued at US$ 115.8 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 To 2031.
Key Takeaways
Key players: Key players operating in the Cardiac Valvulotome Market Growth are LeMaitre, INVAMED, GeoSurgical, LimFlow, Inc., B. Braun SE, Teleflex Incorporated, StarFish Product Engineering Inc., Koven Technology Canada Inc., Andramed, Zgrum Medical, BD, PEAK SURGICAL, and Symmetry Surgical Inc.
Key opportunities: The key opportunities in the cardiac valvulotome market include the introduction of next-generation valvulotomes integrating visualization and cutting technologies and the development of valvulotomes suitable for transvascular and transcatheter procedures.
Global expansion: Major players in the market are focusing on expanding their geographical footprint in high-growth emerging markets such as China, India, Brazil, and countries in the Middle East and Africa through collaborations with regional distributors and partners.
Market drivers: The primary driver for the cardiac valvulotome market growth is the increasing incidence of cardiac valve diseases globally owing to the rapidly growing geriatric population and rising prevalence of obesity, diabetes, and hypertension. According to WHO, cardiovascular diseases are the leading cause of mortality globally, taking an estimated 17.9 million lives each year.
PEST Analysis
Political: Regulations regarding the usage and approval of cardiac valvulotome procedures and medical devices are becoming more stringent. Regulatory bodies are ensuring high quality and safety standards are met.
Economic: Growing prevalence of cardiac diseases and rising healthcare spending are driving the need for valvulotome procedures, supporting market growth. However, high costs associated can hinder widespread adoption.
Social: Awareness about benefits of minimally invasive cardiac procedures in reducing recovery time is increasing. People are willing to opt for such treatments for better quality of life.
Technological: Advanced valvulotome designs with improved material and blade configurations are becoming available. Some products offer features like controlled cuts, precision guiding, and safety retraction mechanisms. Development of robotics-assisted valvulotome systems is also on the horizon.
The market is concentrated in regions with advanced healthcare infrastructure and higher spending ability. North America currently holds the largest share due to availability of reimbursements and routine health checks. Asia Pacific is growing at a fast pace led by China and India. Rising medical tourism and expanding healthcare facilities in developing countries are contributing to this growth.
Another fast emerging region is Latin America, driven by government initiatives to fix congenital heart defects and extend insurance coverage. Countries like Brazil and Mexico are seeing heavy demand with increased accessibility and affordability of these minimally invasive treatments.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
